Senthil K Radhakrishnan
Overview
Explore the profile of Senthil K Radhakrishnan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
28
Citations
1369
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Elshazly A, Hosseini N, Shen S, Neely V, Harada H, Grant S, et al.
bioRxiv
. 2025 Feb;
PMID: 39974947
Proteasome inhibitor drugs are currently used in the clinic to treat multiple myeloma and mantle cell lymphoma. These inhibitors cause accumulation of undegraded proteins, thus inducing proteotoxic stress and consequent...
2.
Chougoni K, Neely V, Ding B, Oduah E, Lam V, Hu B, et al.
Cancer Res Commun
. 2024 Sep;
4(10):2685-2698.
PMID: 39302104
NSCLC is the leading cause of cancer death due, in part, to a lack of active therapies in advanced disease. We demonstrate that combination therapy with a proteasome inhibitor, BH3-mimetic,...
3.
Floros K, Fairchild Jr C, Li J, Zhang K, Roberts J, Kurupi R, et al.
Res Sq
. 2024 Jun;
PMID: 38883782
Synovial Sarcoma (SS) is driven by the SS18::SSX fusion oncoprotein and is ultimately refractory to therapeutic approaches. SS18::SSX alters ATP-dependent chromatin remodeling BAF (mammalian SWI/SNF) complexes, leading to the degradation...
4.
Shen S, Radhakrishnan S, Harrell J, Puchalapalli M, Koblinski J, Clevenger C
Endocrinology
. 2024 May;
165(6).
PMID: 38713636
Prolactin and its receptor (PRLr) in humans are significantly involved in breast cancer pathogenesis. The intermediate form of human PRLr (hPRLrI) is produced by alternative splicing and has a novel...
5.
Floros K, Fairchild C, Li J, Zhang K, Roberts J, Kurupi R, et al.
bioRxiv
. 2024 May;
PMID: 38712286
Synovial Sarcoma (SS) is driven by the SS18::SSX fusion oncoprotein. and is ultimately refractory to therapeutic approaches. SS18::SSX alters ATP-dependent chromatin remodeling BAF (mammalian SWI/SNF) complexes, leading to the degradation...
6.
Ward M, Vangala J, Kamber Kaya H, Byers H, Hosseini N, Diaz A, et al.
J Cell Biol
. 2024 Apr;
223(6).
PMID: 38656405
Cells exposed to proteotoxic stress invoke adaptive responses aimed at restoring proteostasis. Our previous studies have established a firm role for the transcription factor Nuclear factor-erythroid derived-2-related factor-1 (Nrf1) in...
7.
Li J, Purser N, Liwocha J, Scott D, Byers H, Steigenberger B, et al.
Mol Cell
. 2024 Feb;
84(7):1304-1320.e16.
PMID: 38382526
Cullin-RING ligases (CRLs) ubiquitylate specific substrates selected from other cellular proteins. Substrate discrimination and ubiquitin transferase activity were thought to be strictly separated. Substrates are recognized by substrate receptors, such...
8.
Byers H, Brooks A, Vangala J, Grible J, Feygin A, Clevenger C, et al.
Sci Rep
. 2023 Sep;
13(1):15843.
PMID: 37739987
Proteasomes are multi-subunit complexes that specialize in protein degradation. Cancer cells exhibit a heightened dependence on proteasome activity, presumably to support their enhanced proliferation and other cancer-related characteristics. Here, a...
9.
Kamber Kaya H, Radhakrishnan S
Trends Genet
. 2020 Sep;
37(2):160-173.
PMID: 32988635
The key to a healthy mammalian cell lies in properly functioning proteolytic machineries called proteasomes. The proteasomes are multisubunit complexes that catalyze the degradation of unwanted proteins and also control...
10.
Northrop A, Byers H, Radhakrishnan S
Mol Biol Cell
. 2020 Sep;
31(20):2158-2163.
PMID: 32924844
The ability to sense proteasome insufficiency and respond by directing the transcriptional synthesis of de novo proteasomes is a trait that is conserved in evolution and is found in organisms...